Elusys is a privately held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using its proprietary Heteropolymer antibodies for the treatment of infectious disease. Current venture investors include Essex Woodlands Health Ventures, Invesco Private Capital, Crescendo Ventures, EagleAdvisors and the Legg Mason Emerald Fund. The company s most advanced product, Anthim, is a therapeutic for the treatment of Anthrax, a category A biowarfare agent. Elusys pre-clinical pipeline also contains product candidates for lupus, lymphoma and deep vein thrombosis. Elusys Therapeutics is headquartered in Pine Brook, N.J.